drugset
drugset / Trial / NCT05680740

A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis

NCT05680740 ↗

Phase 4 Completed 34 enrolled Organon and Co
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, multi-center study to evaluate the efficacy and safety of VTAMA (tapinarof) cream, 1% in adults with intertriginous psoriasis

Timeline

Start
2022-12-27
Primary completion
2023-05-18
Completion
2023-05-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Tapinarof Other / unclassified 1 % Topical

Indications

psoriasis